Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

QUOTED. 13 November 2019. Ted Tanner.

Executive Summary

Ted Tanner, CTO of IBM Watson Health, recently sat down with Medtech Insight to talk about his plans for developing a blockchain-based data information exchange network in partnership with health organizations to create 'frictionless' computing. See what Tanner said about it here.

You may also be interested in...



Exec Chat: XMed2019: How IBM Watson Health's CTO Uses Blockchain To Eliminate 'Friction Points' In Health Care

Ted Tanner, the new chief technology officer and chief architect of IBM Watson Health, recently sat down with Medtech Insight to discuss his plans for the company. In 2020, IBM will start testing the first use cases of its blockchain-based data information exchange network, a partnership with several health-care organizations, aimed at reducing administrative errors and costs. Tanner refers to blockchain as an "enablement platform" that augments computing power.

Entries Begin To Roll In For 2024 Industry Awards

Entries have now begun rolling in for the Global Generics & Biosimilars Awards, which returns to Milan this October, Free to enter and attend, the ceremony recognizes the top achievements across the generics, biosimilars and value added medicines industries.

‘I Would Love To Have All The Biologic Assets’ – Formycon’s Glombitza Sets Out Portfolio Approach

In the second part of an exclusive interview, Formycon CEO Stefan Glombitza talks to Generics Bulletin about key regulatory developments in Europe and the US, the firm’s portfolio selection strategy, and upcoming milestones on the horizon.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT125895

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel